Analysis of HIV drug resistance has identified sites on HIV target genes that convey
resistance to particular classes of agents. These data may be especially important in …

Efavirenz, a non-nucleoside reverse transcriptase inhibitor, has been an important
component of the treatment of HIV infection for 10 years and has contributed significantly to …

Background. Evaluation of pretreatment HIV genotyping is needed globally to guide
treatment programs. We examined the association of pretreatment (baseline) drug …

Most of the current knowledge on antiretroviral (ARV) drug development and resistance is
based on the study of subtype B of HIV-1, which only accounts for 10% of the worldwide HIV …

Combined HIV antiretroviral therapy (cART) has been effective except if drug resistance
emerges. As cART has been rolled out in low-income countries, drug resistance has …

Limited data exist on HIV‐1 drug resistance patterns in South Africa following second‐line
protease‐inhibitor containing regimen failure. This study examined drug resistance patterns …

The vast majority of reports on drug resistance deal with subtype B infections in developed
countries, and this is largely due to historical delays in access to antiretroviral therapy (ART) …

Most patients failing antiretroviral treatment in Uganda continue to fail their treatment
regimen even if a dominant drug-resistant HIV-1 genotype is not detected. In a recent …

Ninety percent of HIV-1-infected people worldwide harbour non-subtype B variants of HIV-1.
Yet knowledge of resistance mutations in non-B HIV-1 and their clinical relevance is limited …

The HIV-1 has evolved swiftly and the scenario of HIV-1 genetic diversity is constantly
changing. In South America, recombinant forms of subtypes B, F1, and BF1 have historically …